Biotechnology

Friday Sep 01, 2023 - 2:35 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs

BiondVax (NASDAQ: BVXV), a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently received coverage in analysis by Aegis Capital Corp. The report, which reiterated a buy recommendation and $70 target price for BVXV, contained analysis highlighting a deal valued at approximately $2.4 billion for…

Friday Sep 01, 2023 - 12:24 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Patent Protection in ‘Some of the Most Important Markets in the World’

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently received a patent from the China National Intellectual Property Administration. “The granted patent broadly covers the use of the company’s drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers. The REQORSA gene therapy in combination with Keytruda is…

Wednesday Aug 30, 2023 - 10:55 am

InvestorNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Congratulates GEDiCube on New Joint Effort Clinical Trials

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, released a statement congratulating GEDiCube on its joint effort to accelerate early diagnosis of cancer in clinical trials. GEDiCube is partnering with NVIDIA Inception on clinical trials focused on advancing a unique platform for early cancer detection. The platform combines techniques for boosting…

Friday Aug 25, 2023 - 2:01 pm

InvestorNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is Fast on the Trail to Target IL

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, in-licensed the next antibody from the Max Planck Institute – a NanoAb designed to target interleukin-17 (“IL-17”) for the treatment of psoriasis, HS and other important indications. “BiondVax is now fast on the trail of developing what could be a very…

Thursday Aug 24, 2023 - 12:42 pm

InvestorNewsBreaks – SOHM, Inc. (SHMN) Announces Strategic Board Appointment of Dr. Krishna Bhat, MD, Ph.D., FACC

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, today announced the appointment of Dr. Krishna Bhat, MD, Ph.D., FACC, an experienced bioscientist and cardiologist, to serve on its advisory board as a chief medical advisor. According to the update, Dr. Bhat has a practice of over 35 years in the field of clinical and…

Thursday Aug 24, 2023 - 10:00 am

InvestorNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, will be represented at the 25th annual H.C. Wainwright Global Investment Conference. The company announced that CEO Brian Markson will be participating in a fireside chat during the event, which is scheduled for Sept.…

Wednesday Aug 23, 2023 - 1:45 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes Launching IND Program on DehydraTECH-CBD for Hypertension

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that its groundbreaking research utilizing its patented DehydraTECH(TM)-processed cannabidiol (“DehydraTECH-CBD”) has been published in eight peer-reviewed articles across six different publications. “The most recent publication in June 2023 in the peer-reviewed International Journal of Molecular Sciences is ‘Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study.’…

Wednesday Aug 23, 2023 - 1:16 pm

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Eyes Clear Path to IND Submission for Innovative Cancer Platform

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), announced that it remains confident in submitting an Investigational New Drug Application (“IND”) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the U.S. Food and Drug Administration (“FDA”) on the company’s Pre-IND submission. The company’s proprietary, novel technology uses cell- and gene-therapy to promote renewed immune response against solid tumors. “We are…

Tuesday Aug 22, 2023 - 11:48 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints Regulatory Expert as It Drives Important Clinical Programs Forward

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its appointment of Suzanne Thornton-Jones, Ph.D. as senior vice president, regulatory affairs. Dr. Thornton-Jones will leverage her expertise to guide Genprex’s regulatory submissions and strategy for its pipeline of gene therapy drug candidates. “We are delighted to welcome Dr. Thornton-Jones to the Genprex team…

Monday Aug 21, 2023 - 3:21 pm

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces Results of Annual Meeting

IGC Pharma (NYSE American: IGC) has announced that during its annual meeting of stockholders scheduled for and convened on Aug. 18, 2023, (the “annual meeting”), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 26, 2023, were passed by the requisite vote of the stockholders. Only stockholders of record as of the record date of June…

Monday Aug 21, 2023 - 12:27 pm

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Congratulates GEDi Cube on Appointment of Expert in Clinical Medicine and Digital Health

Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy, on Aug. 9 announced an exclusive, binding letter of intent with GEDi Cube. Today Renovaro BioSciences congratulated GEDi Cube on its appointment of Dr. Lester Russell as its chief medical officer. “We are excited about the appointment of Dr. Russell,” said Dr. Mark Dybul, CEO of Renovaro BioSciences. “As a seasoned…

Friday Aug 18, 2023 - 11:09 am

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Discusses Substantial Scientific, Product Development Advances in Letter to Shareholders

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), earlier this year issued a letter to shareholders from its CEO Mark Dybul, MD, in which Dr. Dybul discussed scientific and product development advances and plans for the future. The advances included independently conducted studies that showed remarkably promising results, demonstrating and confirming proof-of-concept for the company’s cell-gene-immunotherapy for pancreatic cancer and, potentially, other solid tumors, as well…

Thursday Aug 17, 2023 - 1:28 pm

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Announces Presentation of ‘Impressive’ Results from Proof-of-Concept Studies

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), in March of 2023 announced that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy for cancer, presented proof-of-concept data from two sets of humanized mouse studies conducted independently by her laboratory at the University of California, Los Angeles (“UCLA”). According to the announcement, the experiments demonstrated highly significant reductions in the weight and volume…

Thursday Aug 17, 2023 - 12:23 pm

InvestorNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Spotlighted in New Cantor Fitzgerald Research Brief

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, is featured in a recent Cantor Fitzgerald research brief. Noting that the stock “looks even more interesting post solid quarter and ahead of potential strategic acquisition,” the research brief reiterated its previous Overweight (“OW”)…

Wednesday Aug 16, 2023 - 12:49 pm

InvestorNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Enters into Agreements for $5M Registered Direct Offering

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, has entered into definitive agreements. The offering is expected to close on or about Aug. 18, 2023, and will be subject to customary closing conditions. The company anticipates gross proceeds from the registered direct offering…

Wednesday Aug 16, 2023 - 11:43 am

InvestorNewsBreaks – Jupiter Wellness Inc.’s (NASDAQ: JUPW) Subsidiary Announces Pricing of Its IPO

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced that SRM Entertainment Inc. (NASDAQ: SRM), currently a subsidiary of the company, announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a price to the public of $5.00 per share. Gross proceeds from the offering are expected to be $6.25 million. The shares of…

Wednesday Aug 16, 2023 - 11:36 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is featured in a recent Aegis Capital Corp. research report. Aegis titled the report “Good Things Coming” and gave BVXV a Buy rating. The research report noted that BiondVax has signed an exclusive worldwide license agreement to develop and commercialize…

Wednesday Aug 16, 2023 - 11:06 am

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Eyes Bright Future in Advancing Potentially Curative Therapies

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), is focused on advancing treatments for some of the world’s deadliest diseases. In late 2022, the company announced the award of a U.S. patent for its oncology platform, as well as promising early results in studies conducted in conjunction with Dr. Ana Jewett at UCLA. Scientists at the Fred Hutchinson Cancer Center were also, at that time, conducting…

Tuesday Aug 15, 2023 - 1:20 pm

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Committed to Rapid Advancement of Its Proprietary Oncology Platform

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), in late 2022, was awarded a U.S. patent for its proprietary cancer treatment platform that could potentially be used to induce life-long remission from some of the world’s deadliest solid tumors. “We are incredibly excited to have been awarded this patent for Enochian’s allogeneic cell and gene therapy cancer treatment platform, especially following promising early study results,” said…

Monday Aug 14, 2023 - 2:33 pm

InvestorNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Announces Q2 2023 Results, Strategic Business Review Update

RVL Pharmaceuticals (NASDAQ: RVLP) is a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. The company today announced financial results for the three months ended June 30, 2023, and provided an update on its business review. “During the past several months, we have focused on expense reduction to…

Monday Aug 14, 2023 - 11:36 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2023 Results, Presents Updated Findings from Potentially Pivotal Study of Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its financial results for the quarter ended June 30, 2023, provided a corporate update and reiterated upcoming milestones. “We are approaching the most important milestone to date since we launched CNS Pharma. We are just a few…

Friday Aug 11, 2023 - 1:56 pm

InvestorNewsBreaks – XSurgical Schedules Webinar to Report Quarter Results, Progress

XSurgical, an artificial intelligence surgical robotics company, is hosting an upcoming webinar to report on the company’s quarterly progress and major achievements. Slated for Aug. 24, 2023, at 9 a.m. PST, the webinar will feature key XSurgical leaders, including cofounder and CEO Dr. Gianluca De Novi, board chair Michele Marzola and board of advisors member Arnon Krongrad. XSurgical is bringing an innovative, unique approach to the surgical…

Friday Aug 11, 2023 - 1:19 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting on its financial results for the second quarter ended June 30, 2023; the report also included a business update. Highlights of the report include R&D expenses for the quarter totaled $1.45 million compared with $1.97 million for the…

Friday Aug 11, 2023 - 12:11 pm

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Releases Updated Information Regarding SRM Entertainment Spin-Off, Closes on Safety Shot Acquisition

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, has released the updated payment date for the distribution of shares of common stock, par value $0.0001 per share, of SRM Entertainment Inc. SRM Entertainment is currently a majority-owned subsidiary of Jupiter Wellness. According to the announcement, the date to effect the spin-off of the SRM business is planned for Aug.…

Friday Aug 11, 2023 - 9:33 am

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q2 2023 Financial Report, Corporate Update

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, is reporting its financial and operational results for the second quarter ended June 30, 2023. Highlights of the report include the closing of a $25 million secondary offering and $1.5 million registered direct offering, resulting in gross proceeds for HeartBeam…

Thursday Aug 10, 2023 - 11:50 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Granted FDA Orphan Drug Designation for REQORSA(R) for Patients with SCLC

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that the United States Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to the company’s lead drug candidate, REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid), for the treatment of small cell lung cancer (“SCLC”). In addition to ODD for the treatment of SCLC,…

Wednesday Aug 09, 2023 - 12:45 pm

InvestorNewsBreaks – HippoFi Inc. (ORHB) Collaborates to Deliver One-of-a-Kind Technology Across US Market

HippoFi (OTC: ORHB), a leading health care technology company and authority in spinal biologics, today announced its execution of an exclusive deal with Italian biomedical manufacturing company, BPB Medica. This comes as HippoFi’s PUR Biologics is preparing to launch PURmarrow360 throughout the U.S., aiming to provide a safe and simple surgical device, specifically designed to selectively capture a patient’s own bone marrow aspirate (“BMA”) and…

Wednesday Aug 09, 2023 - 11:27 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Positive Efficacy Results from Clinical Study of NoStingz

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced data from a recent clinical study of NoStingz, its proprietary topical sunscreen formulated to protect users from jellyfish, sea lice and UVA/UVB rays. According to the update, Portuguese man-o’-war (“MOW”), a marine hydrozoan closely related to jellyfish, has a powerful sting that has been known to kill humans. The present study…

Wednesday Aug 09, 2023 - 11:00 am

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces First Peer-Reviewed Publication Based on Its VECG Technology

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for AI. The company today announced the publication of a foundational study demonstrating the ability of its VECG platform to detect the presence of coronary artery blockages. The publication* appeared in JACC:…

Tuesday Aug 08, 2023 - 12:34 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Appoints Deborah Castillo to Lead Regulatory Strategy and Execution

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for AI. The company today announced its appointment of Deborah Castillo, PhD, as vice president of regulatory affairs. An experienced biomedical engineer with extensive knowledge of FDA, EU and Health Canada regulations,…

Monday Aug 07, 2023 - 1:06 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Distinguished with Unique Capabilities

CNS Pharmaceuticals (NASDAQ: CNSP), a Texas-based cancer drug innovator, is focused on advancing its potentially pivotal clinical trial to track the effectiveness of drug candidate Berubicin in treating glioblastoma (“GBM”) brain cancers. Berubicin has already produced one patient with over 15 years of GBM survival. “Berubicin distinguishes itself by being virtually unique in its status as a cancer-fighting anthracycline that crosses the blood-brain barrier to…

Friday Aug 04, 2023 - 3:33 pm

InvestorNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Third Fast Track Designation Validates REQORSA(R)’s Potential

Genprex (NASDAQ: GNPX), a gene therapy company, recently received U.S. FDA Fast Track Designation (“FTD”) for its lead product candidate, REQORSA(R) immunogene therapy, in combination with Tecentriq(R), a cancer immunotherapy treatment developed and sold by Genentech, Inc., in patients with extensive-stage small cell lung cancer (“ES-SCLC”) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. “The FTD is for…

Friday Aug 04, 2023 - 10:06 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Delays SRM Entertainment Inc. Spin-Off, Distribution of Common Stock

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, has temporarily postponed the spin-off and common stock distribution of its majority-owned subsidiary, SRM Entertainment Inc. According to the announcement, the distribution of shares of common stock at $0.0001 per share has been delayed; the distribution had been planned for Aug. 3, 2023, with the trading date of SRM common stock…

Thursday Aug 03, 2023 - 11:37 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports on Berubicin Pivotal Study, Announces Participation in Biotech Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, released an update on its ongoing clinical study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer. According to the report, the company continues to see rapid progression and acceleration of enrollment for the…

Wednesday Aug 02, 2023 - 10:34 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Launch UNBUZZD

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced its entry into a definitive agreement with Celly Nutrition Inc. to grant exclusive rights to recreational applications for FSD Pharma’s alcohol misuse technology and launch UNBUZZD. A revolutionary, rapid…

Wednesday Aug 02, 2023 - 10:28 am

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Releases Anticipated Payment Date for SRM Entertainment Common Stock Distribution

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, is reporting the payment date for the distribution of shares of common stock, par value $0.0001 per share, of SRM Entertainment Inc. The announcement noted that the payment date remains subject to SRM’s amended registration statement on form S-1 along with the approval of the listing of the SRM common stock…

Wednesday Aug 02, 2023 - 10:16 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Details About Public Offering, Begins Dosing in Final Phase 2 Trial Cohort

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting the price and size of the public offering it announced earlier this week. According to the company, 24,264,706 units of the company will be sold at a price of $0.34 per unit, resulting in an estimated $8.25 million in gross…

Wednesday Aug 02, 2023 - 9:38 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Granted Extension to Regain NASDAQ Compliance

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, received an extension from NASDAQ to regain compliance with listing rules. The extension, which is good until Oct. 30, 2023, was granted after NASDAQ reviewed BiondVax’s detailed plan to regain compliance. BiondVax submitted the plan after receiving a May 1,…

Tuesday Aug 01, 2023 - 12:07 pm

InvestorNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Names New Advisory Board Member

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, has announced a new member of its advisory board. David Long, cofounder and CEO of Orangetheory Fitness, has joined JUPW’s board to support the company’s launch of its newest product: Safety Shot. Long previously served on GBB Drink Lab’s advisory board, playing a key role in guiding the development and marketing…

Tuesday Aug 01, 2023 - 10:47 am

InvestorNewsBreaks – Ocean Biomedical Inc. (NASDAQ: OCEA) Shares Promising Results on World Lung Cancer Day

On World Lung Cancer Day, Ocean Biomedical (NASDAQ: OCEA) shared details of its multipronged lung cancer program built on novel immunotherapy discoveries by Scientific Co-founder Dr. Jack A. Elias. According to the announcement, Dr. Elias and his team have revealed that Chitinase 3-like-1 (“CHi3L1”) is a master regulator that inhibits antitumor immune responses. Ocean Biomedical’s lung cancer program is advancing several approaches to reversing immune…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions